STAGE III UTERINE CORPUS CARCINOMA OR CARCINOSARCOMA AJCC V8
Clinical trials for STAGE III UTERINE CORPUS CARCINOMA OR CARCINOSARCOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III UTERINE CORPUS CARCINOMA OR CARCINOSARCOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III UTERINE CORPUS CARCINOMA OR CARCINOSARCOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets Hard-to-Treat HER2 cancers
Disease control OngoingThis early-stage study tests a combination of two drugs—trastuzumab deruxtecan (DS-8201a) and ceralasertib—in people with advanced solid tumors that have a HER2 mutation. The first part finds the safest dose and checks side effects. The second part compares the combo to DS-8201a …
Matched conditions: STAGE III UTERINE CORPUS CARCINOMA OR CARCINOSARCOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC
-
New drug duo shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis study tested a combination of two drugs, cabozantinib and nivolumab, in 82 people with advanced, recurrent, or metastatic endometrial cancer. The goal was to see if the combo could slow or stop cancer growth. Cabozantinib blocks enzymes that help tumors grow, while nivolumab…
Matched conditions: STAGE III UTERINE CORPUS CARCINOMA OR CARCINOSARCOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
Immunotherapy plus chemo shows promise for tough endometrial cancers
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced or recurrent endometrial cancer live longer without the disease getting worse. About 800 participants with stage III, IV, or recur…
Matched conditions: STAGE III UTERINE CORPUS CARCINOMA OR CARCINOSARCOMA AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New drug combo targets returned ovarian and uterine cancers
Disease control OngoingThis early-phase trial tests the safety and best dose of two drugs, APG-1252 and cobimetinib, given together to people whose ovarian or endometrial cancer has come back. The drugs work by blocking proteins that help cancer cells survive and grow. The goal is to see if the combina…
Matched conditions: STAGE III UTERINE CORPUS CARCINOMA OR CARCINOSARCOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 11, 2026 12:10 UTC